Investor Aisling Capital IV, LP
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Aisling Capital IV, LP . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2024-11-12 13G/A ELEV / Elevation Oncology, Inc. 2,878,296 2,913,005
2024-02-06 13G/A ELEV / Elevation Oncology, Inc. 2,876,561 2,878,296
2023-03-03 13D/A MRKR / Marker Therapeutics, Inc. 3,500,000 464,285
2023-02-08 13G/A ELEV / Elevation Oncology, Inc. 2,866,148 2,876,561
2022-02-14 13G ELEV / Elevation Oncology, Inc. 2,866,148
2022-02-14 13G VIRX / Viracta Therapeutics, Inc. 10,100,000 288,571
2019-07-15 13G/A VIRX / Viracta Therapeutics, Inc. 7,600,000 10,100,000
2019-02-05 13G/A PTGX / Protagonist Therapeutics, Inc. 1,015,761 0
2019-01-24 13G/A VIRX / Viracta Therapeutics, Inc. 2,975,000 7,600,000
2018-10-19 13D MRKR / Marker Therapeutics, Inc. 3,500,000
2018-04-09 13G ZSAN / Zosano Pharma Corp 1,600,000
2018-02-07 13G/A PTGX / Protagonist Therapeutics, Inc. 833,333 1,015,761
2018-02-07 13G/A VIRX / Viracta Therapeutics, Inc. 1,293,574 2,975,000
2017-10-05 13G ONCT / Oncternal Therapeutics, Inc. 1,356,697
2017-01-06 13G VIRX / Viracta Therapeutics, Inc. 1,293,574
2016-09-12 13G PTGX / Protagonist Therapeutics, Inc. 833,333